Hetero Labs seeks emergency use nod from India for Merck’s Covid-19 drug

Merck tapped several Indian generic drugmakers between March and April, including Cipla and Dr Reddy’s Laboratories, to expand the drug’s production and conduct trials, hastening its availability in India to address a second wave of infections. The partnerships gave these companies licence to make and supply molnupiravir to India and more than 100 low-and middle-income countries after approvals or emergency authorisations by local regulatory agencies, Merck said in late April.

Hetero said the late-stage trial of molnupiravir, conducted at Covid-19 dedicated hospital sites across India, looked at the drug’s efficacy and safety in patients with mild Covid-19. The data showed the antiviral drug resulted in statistically significant fewer hospital admissions, faster recovery time and early negative SARS-CoV-2 RT PCR results. Coronavirus cases in India have declined from a devastating peak in April and May. However, health experts have said the country should brace for a third wave by October.

Molnupiravir is currently being tested in a global late-stage study by Merck and partner Ridgeback, with the trial data expected in the fall of 2021.

From the homepage

Pakistani ‘person of interest’ arrested recently was in touch with Sonam Wangchuk, sent reports across border, claims Ladakh DGP

IAS officer removed for ‘administrative reasons’ after technical glitches at PM’s Rajasthan rally

Five killed, one critical as Thar crashes into divider on Delhi-Jaipur Expressway